Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial
Sequential treatment with bortezomib and sorafenib followed by decitabine is feasible and demonstrates acceptable safety in AML. Although the biologic modulation of miR-29b was variable, this trial provides a proof of concept for pharmacodynamic-guided dose finding in epigenetic therapy combinations.
Authors
- Shivani Handa (ORCID: https://orcid.org/0000-0002-1932-6209)
- Sumithira Vasu
- Rebecca B. Klisovic (ORCID: https://orcid.org/0000-0001-6028-7347)
- Bhavana Bhatnagar
- Guido I. Marcucci
- Don M. Benson
- Qiuhong Zhao
- Tamanna Haque (ORCID: https://orcid.org/0000-0003-0589-9038)
- Kristin Koenig
- Alison R. Walker
- Alice S. Mims
- Ramiro Garzon
Institutions
- Cleveland Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Moffitt Cancer Center (US)
- City of Hope (US)
- University Hospitals Seidman Cancer Center (US)
- Wheeling Hospital (US)
- The Ohio State University (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-12-23
- DOI
- https://doi.org/10.3390/cancers18010045
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ohio State University
- National Cancer Institute